CD276 and breast cancer: Revealed ten immune targets were identifiedCD80, CD276, BTN1A1, HHLA2, LILRA2, NCR3LG1, NECTIN3, PVR, SLAMF9, TNFSF4. Most of these targets have not been assessed as potential targets for breast cancer treatment or studied for their connections to ferroptosis. This study unveiled the potential of these targets as therapeutic options related to ferroptosis in BRCA, introducing a new avenue in BRCA immunotherapy.